Emergent BioSolutions (EBS) Tops Q3 EPS by 31c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.55 --0%
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ESP, VIVO, MLKN, More
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ESP, VIVO, MLKN, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.21, $0.31 better than the analyst estimate of $0.90. Revenue for the quarter came in at $311.8 million versus the consensus estimate of $289.27 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Raymond James Starts Western Alliance Bancorporation (WAL) at Outperform
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
